BioVoice News December 2017-January 2018 Issue 7 Volume 2 | Page 48

tech providers ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: “Regional manufacturing facilities crucial for suppliers” Besides sharing his views on the current R&D trends, manufacturing practices and market scenario pertaining to biosupplier industry, Mr Devashish Ohri, Executive Vice President, Asia/Middle East, Africa (MEA), Avantor in an exclusive interaction with the Biovoice News, also provided insights into his company’s India operations. Read the detailed interview below BY RAHUL KOUL What are the latest trends in raw material products and technology globally? opportunities and technical challenges has increased. The biological systems used to manufacture these drugs are known to be The global market for inherently variable, a biologic-based feature which has therapeutics has important greatly expanded over consequences for the the last decade. The reproducibility, safety emergence of the and efficacy of the biosimilar marketplace resulting desired too has been product. significant. As a result, Process insight and the number of consistency are critical commercial since slight changes 48 BioVoiceNews | Dec 2017 - Jan 2018 can lead to adverse effects, such as immunogenicity, with potentially serious safety implications. In generating biosimilars, it is crucial to ensure that all clinically active attributes of the biotherapeutic, including protein post- translational modifications (PTMs), are accounted for and confirmed. At Avantor, we are actively investigating